Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Capital Expenditures (2018 - 2025)

10x Genomics (TXG) has disclosed Capital Expenditures for 8 consecutive years, with $80000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 100.96% to $80000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $215000.0 through Dec 2025, down 84.09% year-over-year, with the annual reading at $215000.0 for FY2025, 84.09% down from the prior year.
  • Capital Expenditures hit $80000.0 in Q4 2025 for 10x Genomics, up from -$166000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $102.4 million in Q4 2022 to a low of -$56.7 million in Q4 2021.
  • Historically, Capital Expenditures has averaged $9.9 million across 5 years, with a median of $2.3 million in 2022.
  • Biggest YoY gain for Capital Expenditures was 10516.38% in 2021; the steepest drop was 406.14% in 2021.
  • Year by year, Capital Expenditures stood at -$56.7 million in 2021, then surged by 280.59% to $102.4 million in 2022, then plummeted by 96.63% to $3.4 million in 2023, then plummeted by 341.33% to -$8.3 million in 2024, then surged by 100.96% to $80000.0 in 2025.
  • Business Quant data shows Capital Expenditures for TXG at $80000.0 in Q4 2025, -$166000.0 in Q3 2025, and -$1.6 million in Q2 2025.